In the face of immense selection pressure from bacteriophage pre dation 1,2 , bacteria have evolved multiple phageresistance mecha nisms 3 . One such mechanism, abortive infection (Abi), during which a bacteriophageinfected cell altruistically commits suicide to protect the clonal bacterial population 4,5 , can be mediated by a toxinantitoxin (TA) pair 6, 7 . TA pairs are widespread throughout prokaryotes 8 and have been implicated in diverse biological processes, including plasmid maintenance, stress responses and persistence [9] [10] [11] (Fig. 1) . They most often comprise two genes-a toxin gene preceded by an antitoxin gene-usually transcribed from a single promoter. In the cell, the antitoxin and toxin interact, thereby suppressing toxicity. The antitoxin is more labile than the toxin and is preferentially degraded in response to certain stimuli. This leads to a relative increase in toxin concentration that can induce bacteriostasis and cell death.
a r t i c l e s
In the face of immense selection pressure from bacteriophage pre dation 1, 2 , bacteria have evolved multiple phageresistance mecha nisms 3 . One such mechanism, abortive infection (Abi), during which a bacteriophageinfected cell altruistically commits suicide to protect the clonal bacterial population 4, 5 , can be mediated by a toxinantitoxin (TA) pair 6, 7 . TA pairs are widespread throughout prokaryotes 8 and have been implicated in diverse biological processes, including plasmid maintenance, stress responses and persistence [9] [10] [11] (Fig. 1) . They most often comprise two genes-a toxin gene preceded by an antitoxin gene-usually transcribed from a single promoter. In the cell, the antitoxin and toxin interact, thereby suppressing toxicity. The antitoxin is more labile than the toxin and is preferentially degraded in response to certain stimuli. This leads to a relative increase in toxin concentration that can induce bacteriostasis and cell death.
Type I TA systems rely on sequence complementarity between the toxin mRNA and the cisencoded antisense antitoxin mRNA, allowing them to form a doublestranded RNA duplex that is targeted for degra dation (Fig. 1a) . These systems are activated when the level of antitoxin RNA decreases, allowing the toxin mRNA to be translated before it is degraded, as occurs for the hok-sok locus of plasmid R1 (refs. 12,13) . In contrast, type II TA systems have components that interact as proteins (Fig. 1b) . These have been more widely studied and show diverse modes of antitoxin binding to similar core toxin folds. Type II toxins generally act as endoRNases, either as free enzymes [14] [15] [16] or in concert with the ribosome 17, 18 , or as DNA gyrase inhibitors 19, 20 . Other examples include potential proteases and phosphotransferases 21, 22 .
ToxIN, which is encoded by a plasmid from the plant pathogen P. atrosepticum, is a powerful bicistronic Abi system that aborts infection by different phages in multiple host genera 6 . ToxIN is the first example of a new (type III) TA system in which a protein toxin, ToxN, is inhibited by an RNA antitoxin, ToxI 6, 7 (Fig. 1c) . These type III systems are identified by the presence of a repetitive DNA sequence upstream of a transcriptional terminator, which is then followed by a toxin gene. Transcription of this locus is driven by a single constitutive promoter upstream of the repetitive sequence, with the transcriptional terminator acting to regulate the relative levels of repetitive antitoxic RNA to toxin mRNA 6, 7 . Predicted homologs of ToxN are found in plasmids and the chromosomes of diverse bacteria, including human and animal pathogens, human commensals, extremophiles, and soil and marine species 6 . Genes for these protein homologs are usually accompanied by their own specific toxI elements, which are unique in their primary sequences and in their length and number of repeats 6 .
As there was no available structural information on toxins of this type III family, and to understand better how the antitoxic RNA can inhibit its cognate protein, we carried out an Xray crystallographic study of the ToxN-ToxI complex. We present here the structure of the ToxN protein with ToxI RNA, which has allowed identification of the modes of toxin and antitoxin activity and interaction. We fur ther confirmed our results using sitedirected mutagenesis and both in vivo and in vitro functional assays.
RESULTS

The ToxIN complex is a trimeric assembly
Before phage infection, the 19.7kDa toxic Abi protein ToxN (denot ing 'toxin') is inhibited by an upstream repetitive nucleotide sequence called toxI (for 'ToxN inhibitor'), which acts as a noncoding RNA antitoxin 6, 23 . ToxI RNA consists of a tandem array of 5.5 36nt repeats that lack spacers and are therefore entirely contiguous (Fig. 2a) The ≥10 30 bacteriophages on Earth relentlessly drive adaptive coevolution, forcing the generation of protective mechanisms in their bacterial hosts. One such bacterial phage-resistance system, ToxIN, consists of a protein toxin (ToxN) that is inhibited in vivo by a specific RNA antitoxin (ToxI); however, the mechanisms for this toxicity and inhibition have not been defined. Here we present the crystal structure of the ToxN-ToxI complex from Pectobacterium atrosepticum, determined to 2.75-Å resolution. ToxI is a 36-nucleotide noncoding RNA pseudoknot, and three ToxI monomers bind to three ToxN monomers to generate a trimeric ToxN-ToxI complex. Assembly of this complex is mediated entirely through extensive RNA-protein interactions. Furthermore, a 2′-3′ cyclic phosphate at the 3′ end of ToxI, and catalytic residues, identify ToxN as an endoRNase that processes ToxI from a repetitive precursor but is regulated by its own catalytic product. 1 Department of Biochemistry, University of Cambridge, Cambridge, UK. 2 Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand. 3 UCB, Slough, Berkshire, UK. Correspondence should be addressed to G.P.C.S. (gpcs@mole.bio.cam.ac.uk).
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VOLUME 18 NUMBER 2 FEBRUARY 2011 nature structural & molecular biology a r t i c l e s repeat is the fundamental unit that inhibits ToxN toxicity in vivo 6 . We carried out overexpression of the recombinant ToxN-ToxI complex in Escherichia coli, purified the complex as a stable assembly and crys tallized it in both native and selenomethionine (SeMet) forms. The Xray crystal structure was solved using SAD from the SeMet and by molecular replacement of nonisomorphous native protein crystals that diffracted to higher resolution than the derivative ( Table 1) .
The repeating structural unit we observed consists of a ToxN monomer in complex with a 36nt RNA oligomer, which is derived from a fulllength toxI transcript. This monomeric complex formed trimers with a triangu lar architecture (Fig. 2b) . The 3′ end of each ToxI unit is adjacent to the 5′ end of the next unit, in a pseudocontinuous headtotail manner, and each ToxI oligomer interacts extensively with two ToxN molecules-one at each terminus (ToxN binding grooves 1 and 2, Fig. 2b) . Every ToxN molecule thereby interacts with two ToxI molecules over an extended surface (electropositive groove, Fig. 1b) . The buried surface area of ToxN at each proteinRNA interface is roughly 2,000 Å 2 (Supplementary Table 1) , which corresponds to an avid macromolecular interaction 24 and is unlikely to occur through crystal contacts alone. Furthermore, we observed the ToxIN trimer in each of three crystal forms, by both crystallographic and noncrystallographic symmetries. We also confirmed by analytical gel filtration that ToxIN forms a highmolecularweight complex (data not shown), indicating that the trimeric ToxIN is a bio logically relevant macromolecular complex. In this complex, ToxN has a compact globular fold with a highly twisted, sixstranded, antiparallel βsheet core surrounded by four αhelices (Fig. 2c,d) , whereas ToxI forms a convoluted RNA fold that is examined below.
Noncoding, antitoxic ToxI RNA forms a pseudoknot
The repetitive unit in toxI DNA comprises a block of 36 nt (Fig. 3a) . From our previous work 6 , it was predicted that the functional antitoxic ToxI RNA would comprise the transcript of these same 36 nt (Fig. 3a) . In our crystal structure, we did observe a repeat of exactly 36 nt, though each individual 36nt RNA begins 4 nt 5′ of the annotated toxI repeat start (Fig. 3a) . By a succession of single cleavage events that precede each occurrence of these AUUC sequences (Fig. 3a) , a single ToxI transcript of 5.5 repeats could be cut into four of these observed 36nt ToxI RNAs. We therefore propose that the ToxIN trimer folds and assembles following, or in concert with, multiple endoRNase cutting steps that generate the observed ToxI repeat units from the fulllength RNA (Fig. 3a) .
Each ToxI monomer folds as an interdigitated hairpintype pseudoknot 25 , with two singlestranded tails (Figs. 2b and 3b) . The pseudoknot is formed from three sections of ToxI that together make a central helical core of duplex and triplex basepair interactions, inter spersed by two loops (Fig. 3b,c) . Three triplexes zip up the internal fold (Fig. 3d) ; minorgroove singletiered triplexes 1 (G2-C15:A19) and 2 (A20:C14-G3:A20) form classical type II and type I Aminor motifs, respectively 26 . These Aminor motifs widen the minor groove and aid stability of the pseudoknot 26, 27 . Majorgroove triplex 3 is also single tiered: G21:U12-U22:G21 (Fig. 3d) . The interdigitation of G21 is supported by base stacking between U4, G21, G5 and U8 (Fig. 3b, Figure 1 Overview of TA systems. In general, the antitoxic gene (orange) precedes the toxin gene (cyan), as part of a bicistronic operon. (a) In type I TA systems, the short antisense antitoxic RNA forms a duplex with a short region of the full-length mRNA. This duplex prevents translation of the toxin gene and promotes degradation by a cellular RNase such as RNase III. (b) In type II TA systems, the protein antitoxin forms a complex with the protein toxin. Either as a complex or by itself the antitoxic protein often negatively regulates transcription of the operon. Cellular proteases such as Lon and Clp degrade the antitoxin, releasing the toxin. (c) In our proposed type III TA system, a proteinaceous toxin interacts with an antitoxic RNA. A transcriptional terminator (black stem-loop) between the antitoxin and toxin genes regulates relative levels of ToxI and ToxN transcript. As a complex, the toxin and antitoxin negatively regulate transcription. Cellular factor(s) that have yet to be identified trigger toxin activity by degrading the antitoxic RNA, decreasing the level of transcription from the locus or releasing the toxin from the RNA antitoxin. dsRNA, double-stranded RNA. a r t i c l e s as well as an intricate hydrogen bonding network around G5 (Fig. 3d,e) . The fold produces two bulged loops, exposing A6 and U17 (Fig. 3b,c,e) ; A6 interacts extensively with ToxN (see below). Interaction with ToxI occludes the active site of ToxN, accounting for the in vivo inhibition of ToxN activity 6 , to which we now turn.
ToxN acts as an endoRNase
The electron density around the 3′ ribose of ToxI suggested the pres ence of a 2′3′ cyclic phosphate (Fig. 4a) . This cyclic group is formed between the backbone phosphate group from a longer RNA molecule and the 2′ O of the A32 ribose. The 3′ end of one ToxI oligomer is suf ficiently close to the 5′ end of the next to suggest that these two RNAs were previously linked. The ToxI 2′3′ cyclic phosphate is held in the electropositive groove crossing ToxN by an extensive hydrogen bond network that is formed with the side chains of Tyr29, Lys33, Thr52, Ser53 and Lys55, suggesting that this groove is the ToxN active site. The base of A32 is held in a bidentate interaction with the side chain of Gln117 and a single hydrogen bond interaction with the side chain of Tyr110. This precise coordination of A32 suggests base specificity in ToxN activity.
As we showed previously that ToxN S53A was defective for both Abi and toxicity 7 , we expressed and purified this mutant protein for comparison with wildtype ToxN in endpoint RNase assays (Fig. 4b) . We chose substrates to investigate ToxN autoregulation and the regu lation of abundant cellular mRNAs: to examine autoregulation, we produced singlestranded RNA substrates by in vitro transcription from fulllength toxI and the toxN gene, and we chose the ompA and rpoD genes to generate 'highly expressed' substrates. We incubated these substrate RNAs with the purified wildtype ToxN-ToxI and ToxN-ToxI S53A complexes and analyzed the products by agarose gel electrophoresis (Fig. 4b) .
Both the wildtype ToxN and S53A protein samples digested the RNA substrates into discrete banding patterns, suggesting that this degradation was not wholly a result of background RNase contami nation. These background levels were considered to be low, as pre liminary control experiments using fractions from the ToxN protein purification that were devoid of ToxN showed little to no RNase activ ity (data not shown). Unexpectedly, S53A was not inactive, but it did have an altered RNase activity compared with wildtype ToxN and produced different banding patterns for the degradation of the rpoD and ompA RNAs (Fig. 4b) . It is interesting to note that ToxI RNA was degraded by both wildtype ToxN WT and S53A, which indicates that the presence of the antitoxin does not inhibit the RNase activity in vitro (unlike for type II systems with RNase toxins). We suggest that more complex binding kinetics occur in vivo that allow ToxI to inhibit ToxN, and that this is linked to the regulation of stoichiometry that is provided by the transcriptional terminator between toxI and toxN 6, 7 (Fig. 2a) . These results suggest that ToxN has endoRNase activity and is active independently of the ribosome, unlike the RelE family of toxins 17 . The specific RNA fragment patterns generated by ToxNmediated degradation also suggest sequencespecific endoRNase activity (Fig. 4b) .
ToxN forms extensive interactions with ToxI RNA
Helix H3 of ToxN kinks at an approximately 75° angle at residue Asn124, allowing it to wrap across the surface of the protein (Fig. 2d) . The Nterminal section of H3 interacts with a ToxI monomer and, after the kink, the Cterminal section interacts with a second ToxI (Fig. 2b) . H3 residues interacting with ToxI include Leu102, Leu114, Tyr115, Lys116, Gln117, Leu118 and Arg122 (Fig. 5a,b) . ToxN loop residues Glu73 and Asn79 also contribute additional hydrogen bonds to stabilize the ToxIN complex. A further tight interaction occurs where the base of A6 inserts into a pocket formed by the backbone of Phe3 and the side chains of Lys2, Leu99, Leu100 and Leu102 (Fig. 5b) .
Identification of essential toxic and antitoxic residues
Specific mutations confirmed the importance of activesite residues Tyr29, Lys33, Thr52, Lys55, His58 and Gln117 in the Abi phenotype and toxicity (Fig. 5c,d) . We also found that ToxN residues Tyr115 and Arg122, together with ToxI bases A6, A31 and A32, are vital for the ability of the two components to interact in vivo and prevent toxicity (Fig. 5d) . G5 is a key determinant of the pseudoknot fold, and its importance is corroborated by the loss of antitoxicity with a ToxI G5A mutation (Figs. 3e and 5d ).
ToxN and ToxI structural homologs
Using DALI 28 , we unexpectedly identified ToxN as a unique member of the Kidlike toxin family 29 . Three highscoring structural homologs were toxins from type II (proteinprotein) TA systems ( Fig. 6 and Supplementary Figs. 1 and 2) -Kid, MazF and CcdB 14, 19, 30 -with Zscores of 6.1, 4.8 and 6.4, respectively. This structural similarity was unexpected because the sequence similarity is low (only 11.1% identity with Kid) (Supplementary Fig. 1 ). Kid and MazF are endoRNases that cleave free mRNA, whereas CcdB is a DNA gyrase poison; all have proteinaceous antitoxins. The ToxN βcore regions overlap well with those of each homolog; for example, ToxN and Kid strands S1, S2 (ToxN Nterminal region only), S3 and S5 can be superimposed Fig. 6a-c) . Although the core fold is conserved, there are variations in the αhelices and loops that decorate each homologous structure ( Fig. 6 and Supplementary Fig. 2 ). However, some regions of ToxN differ distinctly from all the structural homologs; in particular, although the H3 helices of ToxN and Kid overlay (Fig. 6c) , the Nterminal section of ToxN helix H3 is greatly extended (Fig. 2c,d and Supplementary Fig. 1 ). It is this region of ToxN H3 that has been shown to be a principal site of ToxI RNA recognition (Fig. 5) . Although Kid and ToxN share a similar fold and βcore, the proposed active site of ToxN does not overlay closely with that identified for Kid 31 . The ToxI pseudoknot shares similar structural features with an artificially generated vitamin B 12 aptamer 32 ( Supplementary Fig. 3b) , including the general fold and detailed interactions that stabilize non canonical base pairing in ToxI, such as Aminor motifs 26 . ToxI also has a similar overall fold to a naturally occurring riboswitch that binds a precursor of queuosine 33 (Supplementary Fig. 3c ).
DISCUSSION
Increasing numbers of type I and type II TA systems are being identified and characterized 15, 34, 35 , and bioinformatic approaches have highlighted the widespread nature and abundance of these loci 8, 15, 35, 36 . Notwithstanding this prevalence, there remains some controversy over their exact biological roles. It is necessary, therefore, to expand investigation of the variations and individual phenotypes that are provided by each TA system. Of the known TA systems, type III is predicted to be underrepresented, and the structure reported in this study is the first to be solved for this new type of TA system. Our structure greatly extends the known structural informa tion for TA systems. We have observed the elegant inhibition of an endoRNase toxin by the RNA substrate itself. The fact that this RNA substrate, the antitoxin, folds into a complex pseudoknot, seems to be vital for inhibition of the toxin and is entirely unique throughout known examples of TA systems. After the endoRNase cleavage step, the extensive interaction between the folded RNA surface and the protein surface is thought to maintain the complex in an inert state before activation.
Because of the low sequence similarity between them, we were surprised to find that the ToxN protein is an embellished version of the type II Kid, MazF and CcdB toxins 31 (Fig. 6 and Supplementary  Figs. 1 and 2) . Evolutionarily, this suggests that a simple endoRNase scaffold can be used for multiple purposes, at least for the reduction Figure 4 ToxN has an endoRNase active site. (a) ToxN active site interactions with ToxI. A simulated annealing omit map, at 3.75σ level, was calculated using our model, omitting the proposed 2′-3′ cyclic phosphate group, and is shown in green. Hydrogen bonding interactions within 2.6 Å to 3.5 Å are indicated by black dashed lines, and a water molecule is shown as a red sphere. Coloring is as in Figure 3 . (b) In vitro ToxN RNase assay. The ability of the purified wild-type (WT) ToxN protein and the ToxN S53A mutant to digest in vitro-transcribed RNAs was assessed. RNA substrates were selected to allow investigation of autoregulation (full-length ToxI RNA (5.5 36-nt repeats) and ToxN RNA) and to examine the effect on transcripts of highly active genes (OmpA and RpoD RNA). Protein was mixed with RNA at a 4:1 molar ratio and incubated. The products were analyzed by agarose gel electrophoresis. a r t i c l e s of plasmid loss, for responding to stress or for abortive infection. Whether the scaffold arose through convergent or extensively diver gent evolution is unknown. Clearly, however, by adapting the Kidlike fold, ToxN is able to bind and be inhibited by a ToxI RNA pseudoknot. The fact that the ToxIN trimeric complex was formed entirely through RNA and protein interactions was unexpected.
The presence of a 2′3′ cyclic phosphate indicates that ToxN is an endoRNase (Fig. 4a) . This was also predicted by its structural homology with the endoRNases Kid and MazF; however, as the DNA gyrase inhibitor CcdB is also a homolog, we performed in vitro RNase assays to further investigate ToxN activity (Fig. 4b) . As we were not able to specifically inhibit ToxN with ToxI in vitro, we cannot rule out RNase contamination as contributing to the RNA digestion pat terns. Still, we suggest that the distinct banding patterns that resulted are indicative of an endoRNase with sequence preference, such as is found for Kid and MazF. This proposed RNase activity of ToxN relies upon specific residues to position the substrate and provide catalysis, as shown through mutagenesis studies (Figs. 4b and 5c,d) . We observed some RNase activity of the S53A ToxN mutant, which carries the mutation in the active site. A similar situation is found for other Kid family enzymes, in which substitutions in the active site impair but do not eliminate catalysis, as the residues make distributive interactions to support the substrate. The RNase assay data do suggest a mode of action for ToxN: active ToxN cleaves cellular mRNAs and induces bacteriostasis, which leads to cell death.
As neither additional ToxI nor the copurified ToxI present in the protein samples (Fig. 4b) completely inhibited ToxN in vitro, the question arises as to how stable the ToxIN complex is in vivo: the ToxN protein digests ToxI RNA in vitro and yet is inhibited by ToxI RNA in vivo, so is the same level of turnover of ToxI occurring in vivo? If so, the cellular levels of ToxI must be sufficient to overpower the activity of ToxN and thereby hold ToxN in an inactive complex. There is certainly potential for this to be the case, as indicated by our previous experiments, which showed tenfold higher transcription of toxI over toxN, owing to the transcriptional terminator between the two 6, 7 (Fig. 2a) . However, it seems paradoxical that we have been able to crystallize this ToxIN complex, which is potentially dynamic in the cell; the high concentration of protein may have promoted complex formation in the crystallization droplets. When considering the steps to complex formation, the exact stage at which ToxI is cut by ToxN is unknown, and it is important to assess whether this event occurs dur ing formation of the complex, whether this is cotranslational and, if not, how this is influenced by folding of the two components. Further investigation is clearly warranted to fully understand the regulation of these type III systems.
It was also clear that the interaction of ToxI and ToxN is vital for Abi activity and maintenance of the complex in the cell (Fig. 5) . We suggest that abortive infection may be instigated when this complex is disturbed, either through disruption of toxIN transcription or by direct molecular interaction with a phage product (as shown in Fig. 1c) . Furthermore, the noncoding RNA ToxI has a similar topo logy to both an RNA aptamer that binds vitamin B 12 (ref. 32 ) and a queuosine riboswitch 33 (Supplementary Fig. 3 ). Although there is currently no biochemical evidence to support this hypothesis, we sug gest that ToxI may also sense and respond to smallmolecule ligands that could be allosteric modulators. In this way, the ToxIN system or homologs could acquire the capacity to respond to diverse metabolic and environmental cues. This seems a potentially exciting area for further research.
RNA pseudoknots are involved in gene regu lation events and translational frameshifting in tumor viruses and retroviruses 37, 38 , and they also form a component part of human telomerase 39 . Whereas pseudoknots have been artificially developed to bind specific small molecules 32 and even to inhibit proteins such as the HIV1 reverse transcriptase 40 , ToxI is a naturally occurring noncoding RNA pseudoknot that can bind and thereby counter the toxicity of its proteinaceous ligand. Small noncoding RNAs are encoded by a diverse and growing family of genes that are required for the regulation of bacterial physiology 23, 41 . By acting to suppress ToxN as a pseudoknot, ToxI further highlights and extends the impact of small noncoding RNAs in diverse biological processes. Elucidating the manner in which ToxN homologs bind their cognate ToxI RNAs will provide a greater understanding of protein-noncoding RNA pseudoknot interactions, and could enable the potential exploitation of specific molecular rec ognition for therapeutic applications. This structure will underpin fur ther investigations into structurefunction relationships in type III TA systems. In particular, we are interested in defining the mechanisms by which ToxIN is activated by some, but not all, phages to drive a lethal, altruistic Abi response in bacteria.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
ONLINE METHODS
Purification, crystallization and structure determination. The toxN gene was cloned into vector pTYB1 (New England Biolabs), and toxI, together with the natural toxIN promoter, was cloned into pACYC184 (ref. 42 ). These expression vectors were used to cotransform a single strain of E. coli ER2566 (New England Biolabs). The expressed native and SeMetderivatized 43 ToxIN complexes were purified with the aid of a chitinbinding domain and intein tag, followed by HiTrap Q (GE Healthcare) ionexchange chromatography using Fast Protein Liquid Chromatography (Äkta). The protein was dialyzed against 50 mM NaCl, 10 mM TrisHCl, pH 7.5, and 1 mM DTT, then concentrated to ~10 mg ml −1 before use in crystallization trials. Native and SeMet crystals were formed at 18 °C in sitting drops, and SeMet crystals were further optimized using the matrix seeding method 44 The native data from the Native 2 P2 1 2 1 2 1 crystals were processed in HKL2000 and scaled in SCALEPACK2000 (ref. 45) . The native data from the Native 1 crys tals and the SAD data from the SeMet crystals were processed using MOSFLM, SCALA and TRUNCATE in the CCP4 suite 46 of programs (http://www.ccp4. ac.uk/). Heavyatom sites were identified and iteratively improved by using HKL2MAP 47 , autoSHARP 48 and PHENIX 49 , yielding 15 selenium and 3 zinc sites. The figure of merit to 3.2 Å from PHENIX was 0.38. After threefold non crystallographic symmetry averaging, the autobuild mode of PHENIX produced a model with 72 main chain and 39 side chain fragments out of a total of 486 resi dues for a trimeric model. This model clearly showed the helical region 109-121 in both main chain and side chain, and a βsheet including partial βstrands S1, S2, S3, S5 and S6 (Fig. 1c,d) . The map produced was therefore of sufficiently high quality to permit confident interpretation and tracing of the backbone and side chains of ToxN; this was completed using COOT 50 .
The final refined structure of the SeMet crystal contained ToxN residues 1-162. A F o -F c difference map, above 3σ levels, was used to guide the modeling of ToxI RNA in COOT. This structure was used as a search model in molecular replacement calculations to determine both the Native 1 and Native 2 structures, using Phaser 51 . In the 2.75Å structure of the Native 1 ToxIN complex, the final model contains ToxN residues 1-162 and 36 nt of ToxI. The stereochemistry of each model was validated using SFCHECK and PROCHECK in the CCP4 suite of programs. Ramachandran plot values (preferred, allowed, outlier), were as follows for each model: Native 1 (96.9%, 3.1%, 0.0%); Native 2 (95.3%, 4.7%, 0.0%); SeMet (91.8%, 8.2%, 0.0%). Metal ions Co 2+ and Zn 2+ were observed within the Native 1 and SeMet crystals, respectively, in positions suggesting that divalent cations aid ToxI binding. Figures of the ToxIN structure were generated using PyMol (http://pymol.sourceforge.net) and adapted using Adobe Illustrator (CS4; Adobe).
Analysis of ToxN structural homologs.
Structural homologs of ToxN were iden tified using DALI 28 , and the amino acid sequences were aligned with ClustalW2 (ref. 52) . Initial secondarystructure images were produced with ESPript 53 . Structural overlays were made with COOT.
In vitro endpoint RNase assays. The gene for ToxN S53A was cloned into pTYB1 and coexpressed with ToxI as for wildtype ToxN. RNAs were prepared by first cloning the necessary gene into pBluescript (Stratagene), downstream of the T7 RNA polymerase promoter. Plasmid pECA1039 was used as template DNA for toxI and toxN, whereas ompA and rpoD were amplified from E. coli DH5α genomic DNA. These recombinant plasmids were linearized and used as templates for in vitro transcription with T7 RNA polymerase (Fermentas). The resulting RNAs were mixed, when appropriate, with a ToxN protein at a 4:1 protein:RNA molar ratio. The samples were incubated at 37 °C for 1 h and then separated by electrophoresis in a 1.6% agarose, 0.5× TrisBorateEDTA (TBE) gel stained with ethidium bromide.
In vivo phenotypic assays. For Abi assays, the full toxIN locus was mutated by overlap extension PCR and subsequently cloned into pBR322. For toxicity and antitoxicity assays, mutant amplicons for ToxN and ToxI were first generated by overlap extension PCR, then cloned into either pBAD30 (ref. 54) or pTA100 (ref. 6), respectively. In all cases, ToxN proteins had an additional Cterminal Flag tag, which has previously been shown not to adversely affect ToxN activity 6, 7 . Abi assays were performed as described, using phages ΦM1 and ΦS61 (ref. 7) . Abi data is shown as efficiency of plating (EOP) 55 , which is the ratio of plaqueforming units enumerated on a test strain compared to those on a control strain. Toxicity and antitoxicity assays were also performed as described 6 , replacing either the ToxN or ToxI expression plasmid with the test mutant plasmid as required.
